Big, fat demand for weight-loss drugs fuels Eli Lilly stock surge — as market cap hits $1.2 trillion

Eli Lilly stock hit a record high Thursday thanks to a stronger-than-expected earnings report fueled by sales of weight loss drugs Monjuaro and Zepbound.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.